WHO WE ARE
We share a passion for helping our clients grow
For over 40 years, Kx Advisors (operating as the healthcare consulting practice of Kaiser Associates) have provided advisory services to help leading pharmaceutical, biotechnology and medical technology companies fully capitalize on product opportunities, navigate the environment with greater certainty, and maximize the lifetime commercial value of their portfolios.
We do this by conducting comprehensive primary research and data-driven analysis at all stages of the product lifecycle to inform the decision making of sales, marketing and strategy executives.
The Kx approach establishes the required fact base to vet critical decisions and brings together data from disparate sources to develop holistic strategies.
With offices in Washington D.C, London, and Boston, Kx Advisors possesses the unique ability to generate global insights from physicians, thought leaders, patients, competitors, partners, regulators, suppliers, and payers.
The Kx approach establishes the required fact base to vet critical decisions and brings together data from disparate sources to develop holistic strategies.

How we’re different
We focus on growth strategy
Unlike large consulting firms who toggle between operational work and heterogenous strategy work, we live and breathe healthcare growth strategy. As a result, we have developed deep expertise in exploring new business models, evaluating new technologies, entering new markets, and capitalizing on new policies. Our focus drives results.
We prioritize pragmatism and clarity
We pride ourselves on developing elegant solutions to complex problems. We share a passion for helping our clients devise winning strategies and gain organization buy-in through clear business cases, impactful storytelling, and actionable recommendations.
We believe in data-driven decision making
Insight generation and quantitative rigor define our consulting approach. We are experts at designing research to inform quantitative models, developing forecasts in emerging and innovative markets, and quantifying what is difficult to quantify.
We deliver a first-class client experience
We value collaboration and partnership above all else and design our engagements to follow a highly iterative process. We start fast, deliver against compressed timelines and respond to changing client needs with agility. Our senior leaders remain actively involved throughout our engagements and set a high standard of excellence.
Leadership Team
Dan O’Neill
Managing PartnerDan O’Neill is a Managing Partner at Kx Advisors. He is based in Washington, DC.
Dan has significant experience developing commercial growth strategies for leading Pharmaceutical, Medical Device and Health Technology clients. Since joining Kaiser Associates in 2006, Dan has developed expertise across all major therapeutic areas and project types. Specific emphases include commercial due diligence, strategic marketing, product launch planning, market opportunity assessments, and competitive strategy. He has expertise in integrated research and quantitative modeling techniques related to product pricing and forecasting.
Dan started his career in finance and banking where he developed his quantitative background. Dan holds an MBA from the McDonough School of Business at Georgetown University and a BBA from the University of Kentucky.
Bob Serrano
Managing PartnerBob Serrano is a Managing Partner at Kx Advisors. He is based in Washington, DC.
Bob has nearly 20 years of experience in the healthcare industry, specializing in specialty pharma, interventional medicine, and clinical diagnostics. Bob has extensive expertise in building growth strategies across therapeutic areas including oncology, dermatology, neurology, immunology, and cardiology. Prior to Kaiser Associates and Kx Advisors, Bob held several strategy and sales roles at Abbott (now AbbVie), and led North American laboratory marketing for QIAGEN’s molecular diagnostics business.
Bob earned an MBA from the Kellogg School of Management at Northwestern University, and a Master’s in Health Administration and a BS in Nutritional Science from Cornell University.
Sean Vander Linde
PartnerSean Vander Linde is a Partner at Kx Advisors and is based in Washington, DC.
Sean brings deep experience leading engagements across the healthcare value chain with provider, health IT, biopharma, and medical device companies. His expertise includes advising clients on corporate strategy, market opportunity assessments, new product launch, and commercial due diligence. Prior to joining Kaiser Associates and Kx Advisors, he worked at L.E.K. Consulting and PwC focusing on healthcare.
Sean holds an MBA from the Tuck School of Business at Dartmouth and a BA in Political Science from the University of North Carolina at Chapel Hill.
Mudita Vaish
PartnerMudita Vaish is a Partner at Kx Advisors, based in the London office.
She brings over 14 years of experience in the healthcare and life sciences industry, with deep expertise in pharmaceutical commercial launch strategy, data-driven brand planning, and AI-enabled insights. Mudita has advised leading global pharmaceutical companies on market entry, brand planning, and launch execution across multiple therapeutic areas, including oncology, immunology, neurology, and rare diseases.
Chris Waybill
Partner & AI Solutions LeaderChris Waybill is a Partner and AI Solutions Leader based in the San Francisco Bay Area, advising life sciences companies on high-stakes strategic decisions across the asset lifecycle. With over a decade in strategy consulting at Kx Advisors (now BGBx Consulting), he has led more than 200 engagements spanning corporate strategy, new product planning, and commercial strategy and launch planning. His work centers on moments that define asset success, most notably the transitions from Phase 2 to Phase 3 and from Phase 3 to launch, where clinical, commercial, and investment decisions converge. Chris helps clients translate early signals into actionable strategy, shaping evidence generation, competitive positioning, and go-to-market pathways to maximize probability of success and long-term value. Chris brings broad therapeutic area experience, with a primary focus in CNS, dermatology, immunology, and medical aesthetics, and additional depth across medtech and diagnostics, including interventional devices, connected wearables, and advanced diagnostic platforms. As AI Solutions Leader, Chris is redefining how strategy is built and delivered at Kx. He leads efforts to embed AI and technology-enabled capabilities into core workflows, driving faster insight generation, more dynamic decision-making, and scalable, repeatable approaches to complex strategic problems. He holds a B.S.E. in Mechanical Engineering & Materials Science from Duke University.
Sonya Jakawich
PartnerSonya is a Partner at Kx Advisors, based in New York City.
With over 13 years of experience in life sciences strategic advisory, Sonya partners with clients across the healthcare ecosystem to shape early product and portfolio strategies.
Her expertise spans key therapeutic areas such as Oncology, Obesity/T2D, and Immunology. She brings a deep understanding of the scientific and commercial landscape, having worked closely with cross-functional teams at global pharmaceutical companies, emerging biotechs, and venture capital/private equity firms.
Before joining Kx, Sonya held roles at Pfizer and Trinity Life Sciences. She earned her Ph.D. in Neuroscience from the University of Michigan and a B.S. in Cellular and Molecular Biology from the University of Washington.
Outside of work, Sonya is an avid animal advocate, fitness enthusiast, and culinary explorer who enjoys discovering new restaurants and catching the latest shows around the city.
Masha Dumanis
Senior Vice PresidentMasha Dumanis is a Senior Vice President at Kx Advisors and is based at the firm’s Boston office.
Masha is a recognized thought leader and sought out advisor in the MedTech and Digital Health sector, even more so in her areas of deep expertise: Musculoskeletal (MSK) and Women’s Health.
Masha brings to Kx and its clients over 13 years of experience in healthcare strategy consulting supporting companies with growth strategy, Go-To-Market strategy, commercial due diligence, market access, M&A and corporate strategy.
Masha prides herself on establishing deep relationships with clients to understand their needs and to guide them with data driven decision making.
Prior to joining Kx, Masha worked as a Vice President at Health Advances, a Parexel consulting company and served as leader of its MSK practice area. Masha holds an A.B. cum laude in Human Evolutionary Biology from Harvard College. She also serves as Senior Advisor to the Journal of Orthopaedic Experience & Innovation (JOEI).
Jenny Knauss
Senior Vice PresidentJenny has nearly 10 years of experience in the healthcare industry, working across consulting and communications. She brings deep expertise in oncology, both solid tumors and hematological malignancies, and has partnered with Medical Affairs and Commercial clients to inform strategy from early clinical development and landscape analyses through launch planning, brand strategy, and lifecycle management.
Prior to joining Kx, Jenny worked in healthcare consulting at McKinsey & Company and medical communications at BGB Group. She holds a PhD in Cell and Developmental Biology from Weill Cornell Medicine Graduate School of Medical Sciences.
UT Yadav
Senior Vice PresidentUT Yadav is a Senior Vice President at Kx Advisors, based in New York. He brings more than 12 years of experience advising biopharma and biotechnology leaders on critical strategic and commercial decisions across the product lifecycle.
His work spans growth and corporate strategy, new product and portfolio strategy, commercialization, and strategic decision support. UT partners with senior executives and cross-functional teams to evaluate growth opportunities, shape differentiated asset and franchise strategies, and inform development, investment, and go-to-market decisions.
He also helps clients apply AI, advanced analytics, and more efficient approaches to insights generation enabling faster, more rigorous strategic decision-making.
UT has deep experience across oncology, rare diseases, immunology, CNS, and obesity and metabolic disorders. Prior to Kx Advisors, he held commercial strategy roles at Trinity Life Sciences and Deloitte. He completed graduate studies in Bioengineering at Carnegie Mellon University.
Chloe Lok
Vice PresidentChloe is a Vice President with over 10 years of experience in the healthcare industry, leading engagements across pharma, biotech, and digital health. She has deep expertise in rare diseases, immunology, and haematology, and has also worked extensively in respiratory, oncology, psychiatry, and dermatology.
Chloe works closely with global clients to shape asset and portfolio strategy, drive launch planning, and navigate complex commercial and clinical landscapes. She brings robust experience in qualitative and quantitative research, strategic marketing, patient journey mapping, and forecasting. Known for her thoughtful approach and ability to translate insights into clear, actionable strategy, she is passionate about helping teams unlock the full potential of their innovations to improve patient outcomes.
Chloe holds an MSc in Management from Imperial College Business School and a BSc in Biochemistry from the University of Reading.
David Geschwind
Vice PresidentDavid is a Vice President at Kx Advisors and is based in San Francisco, CA.
David has extensive experience leading growth strategy engagements for Pharma, Biotech, MedTech, and Digital Health clients. Specifically, he advises clients on product launch strategy, commercial operations, financial modelling, forecasting, commercial due diligence, pricing, and market access.
David’s therapeutic areas of expertise include interventional medicine, medical aesthetics, eye care, dermatology, and oncology.
David holds a B.A. in Computer Science and Economics from Swarthmore College.
Allie Fascione-Hutchins
Vice PresidentAllie partners with clients to develop both upstream and downstream growth strategies across all of Kx’s key sectors and therapeutic areas. Specifically, she collaborates with biopharmaceutical, medical device, and diagnostic companies, in therapeutic areas including dermatology, critical care, and cardiology. Functionally, Allie’s expertise encompasses market entry strategy, commercial due diligence, opportunity forecasting, long-term franchise planning, and commercial benchmarking. Her work integrates data analytics, competitive intelligence, and voice-of-customer research to create simple and meaningful solutions to complex problems.
Prior to Kx, Allie worked with companies in the financial services and consumer goods industries as a strategy consultant. Allie holds a B.S. with Honors in Economics, with a Mathematical Economics concentration from Haverford College.
Jenette Bellitto
PrincipalJenette Bellitto is a Principal at Kx Advisors based out of the Washington DC office. She partners with clients ranging from emerging biotechs to top global pharmaceutical leaders to unlock growth opportunities and guide high-impact portfolio and launch strategies.
With deep expertise in voice of customer research, opportunity assessment, segmentation, market sizing, and new product strategy, Jenette brings a rigorous, data-driven approach to helping clients navigate complex market dynamics and make confident strategic decisions. Her work spans multiple therapeutic areas, including expertise in psychiatry, immunology, medical aesthetics, and neuroscience, where she has helped shape commercial strategies for both on-market and pipeline assets.
Jenette holds a PhD in Biomedical Engineering from Yale University and a BS in Chemical Engineering from the University of California, Irvine.
Marc Geschwind
PrincipalMarc is a Principal at Kx Advisors and is based in Chapel Hill, NC.
He has led growth strategy engagements across the Medical Aesthetics, Pharma, MedTech, and Animal Health sectors, advising clients on brand and franchise planning, commercial operations, product and portfolio strategy, and commercial due diligence.
Marc has a specific focus in Medical Aesthetics, where he has supported numerous engagements across injectables, skincare, and energy-based devices. Beyond aesthetics, his therapeutic experience includes cardiovascular disease, neurology, orthopedics, inflammatory diseases, and plastic and regenerative medicine.
Marc holds a B.A. in Economics from Swarthmore College.
Tess Huffstater
PrincipalTess Huffstater is a Principal at Kx Advisors, based in Boston, MA. She partners with biopharma and biotech clients to shape growth strategies across oncology, immunology, and rare diseases. Tess focuses on early asset and portfolio strategy, market shaping, and commercial readiness planning, with additional experience in market access. She helps teams define clear value propositions, align cross- functional stakeholders, and prepare for successful launches.
With a background that bridges science and strategy, Tess is passionate about bringing structure and clarity to complex decisions in drug development. She holds a B.S. and M.Eng. in Biomedical Engineering from Cornell University and a Ph.D. in Biomedical Engineering from Vanderbilt University, where her research focused on novel drug targets for kidney disease. Outside of work, Tess enjoys exploring new hiking trails with her dog, discovering local coffee shops and restaurants around Boston, and getting lost in a good book.
Hailey Messenger
PrincipalHailey is a Principal at BGBx Consulting and is based in Washington, DC. She joined BGBx from Kx Advisors and partners with MedTech, Digital Health, and Health IT clients to identify and unlock growth opportunities.
Hailey has extensive experience leading strategy engagements, with a particular emphasis on commercial due diligence, M&A, and commercial growth. With deep expertise in Voice of Customer market research and survey, she is known for uncovering and synthesizing insights into actionable narratives that bring clarity to clients’ biggest strategic questions.
Hailey holds an MPhil in International Relations and Politics from the University of Cambridge and a BA in International Affairs from The George Washington University.
Philipp Langer
PrincipalPhilipp is a Principal at BGBx Consulting based in London. He partners with clients ranging from emerging biotech companies to global pharmaceutical organizations on portfolio and launch strategy across therapeutic areas including immunology, oncology, and rare diseases. Philipp has deep expertise spanning opportunity assessments, competitive wargaming, brand planning, and lifecycle management for pipeline and established assets, helping inform commercialization and investment decisions. He is known for bringing a rigorous and analytically driven approach to complex business challenges, helping clients navigate evolving market dynamics and make confident strategic decisions. Philipp earned an MSci (Hons) in Chemistry and a PhD in Inorganic Chemistry from the University of Nottingham, UK.
Rachel Sachs
PrincipalRachel Sachs is a Principal at BGBx Consulting, based in Boston. She joined BGBx from Kx Advisors and brings deep expertise in oncology across both solid tumors and hematologic malignancies, with additional experience across therapeutic areas including immunology and rare disease. Rachel has significant experience supporting commercial strategy across the asset lifecycle, with particular depth in new product planning, indication prioritization, and opportunity assessments, as well as commercialization and launch strategy and execution. She is known for combining deep therapeutic understanding with data-driven insights to inform strategic direction, helping cross-functional teams align around critical decisions. Rachel holds a B.A. in Biology from Brown University.
Women@Kx
Empowering Our Employees At Every Step
Gender diversity is a keystone in Kx’s inclusive company culture. Our firm supports women at each stage of their career, from new employees to established senior leaders.
Established in 2020, Women@Kx is a monthly meet-up group to provide our consultants with the tools they need to succeed while advancing gender equality in a fast-paced consulting environment. Led by Senior Vice President Masha Dumanis, the group focuses on empowering women and allies by offering opportunities for professional development, mentoring, and building meaningful networks.
What’s happening at Kx Advisors
Locations
Our global reach
Kx New York
Penn1, 250 West 34th Street3rd Floor, Suite 302
New York, NY 10119
Kx Washington, D.C.
1300 Connecticut Avenue NWSuite 510
Washington, DC 20036
Kx London
1 Triton SquareLondon, NW1 3DX
Kx Boston
711 Atlantic Ave, 6th FloorBoston MA 02111

